Aminoguanidine suppresses basal macromolecular extravasation during diabetes mellitus

Microvascular Research

Volumn 59, Issue 1, 2000, Pages 52-60

  Mayhan, William G ^a   Sharpe, Glenda M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Cheek pouch; FITC dextran; Hamsters; In vivo microscopy; Nitric oxide; Permeability

Indexed keywords

AMINOGUANIDINE; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CHEEK POUCH; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME INHIBITION; EXTRAVASATION; HAMSTER; MALE; MICROCIRCULATION; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA; CRICETINAE;

EID: 0033969527     PISSN: 00262862     EISSN: None     Source Type: Journal    
DOI: 10.1006/mvre.1999.2194     Document Type: Article

References (45)

1. Archibald V., Cotter M. A., Keegan A., Cameron N. E. Contraction and relaxation of aortas from diabetic rats: Effects of chronic anti-oxidant and aminoguanidine treatments. Arch. Pharmacol. 353:1996;584-591.
2. Bohlen H. G., Niggl B. A. Arteriolar anatomical and functional abnormalities in juvenile mice with genetic or streptozotocin induced diabetes mellitus. Circ. Res. 45:1979;390-396.
3. Brian J. E., Heistad D. D., Faraci F. M. Mechanisms of endotoxin-induced dilatation of cerebral arterioles. Am. J. Physiol. 269:1995;H783-H788.
4. Bucala R., Tracey K. J., Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest. 87:1991;432-438.
5. Colantuoni A., Berardi P. G., Orefice G. Increased permeability of the microcirculaton to high molecular weight dextran in experimental diabetes, shown by intravital microfluorimetry. J. Nucl. Med. Allied Sci. 23:1979;49-54.
6. Colwell J. A., Halushka P. V., Sarji K. E., Lopes-Virella M. F., Sagel J. Vascular diseases in diabetes: Pathophysiological mechanisms and therapy. Arch. Int. Med. 139:1979;225-230.
7. Corbett J. A., Tilton R. G., Chang K., Hasan K. S., Ido Y., Wang J. L., Sweetland M. A., Lancaster J. R. Jr., Williamson J. R., McDaniel M. L. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes. 41:1992;552-556.
8. Fasching P., Veitl M., Rohac M., Streli C., Schneider B., Waldhausl W., Wagner O. F. Elevated concentrations of circulating adhesion molecules and their association with microvascular complications in insulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 81:1998;4313-4317.
9. Garcia-Leme J., Hamamura L., Migliorini R. H., Leite M. P. Influence of diabetes upon the inflammatory response of the rat. A pharmacological analysis. Eur. J. Pharmacol. 23:1973;74-81.
10. Hsueh W. A., Anderson P. W. Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus. Hypertension. 20:1992;253-263.
11. Hughes S. R., Williams T. J., Brain S. D. Evidence that endogenous nitric oxide modulates oedema formation induced by substance P. Eur. J. Pharmacol. 191:1990;481-484.
12. Ialenti A., Ianaro A., Moncada S., Di Rosa M. Modulation of acute inflammation by endogenous nitric oxide. Eur. J. Pharmacol. 211:1992;177-182.
13. Johnson P. C., Brendel K., Meezan E. Thickened cerebral cortical capillary basement membranes in diabetes. Arch. Pathol. Lab. Med. 106:1982;214-217.
14. Joyner W. L., Mayhan W. G., Johnson R. L., Phares C. K. Microvascular alterations develop in syrian hamsters after the induction of diabetes mellitus by streptozotocin. Diabetes. 30:1981;93-100.
15. Kubes P. Nitric oxide modulates epithelial permeability in the feline small intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 262:1992;G1138-G1142.
16. Kubes P., Granger D. N. Nitric oxide modulates microvascular permeability. Am. J. Physiol. Heart Circ. Physiol. 262:1992;H611-H615.
17. Martin S. Soluble adhesion molecules in Type 1 diabetes mellitus. Horm. Metab. Res. 29:1997;639-642.
18. Mayhan W. G., Joyner W. L. The effect of altering the external calcium concentration and a calcium channel blocker, verapamil, on microvascular leaky sites and dextran clearance in the hamster cheek pouch. Microvasc. Res. 28:1984;159-179.
19. Mayhan W. G. Role of nitric oxide in modulating permeability of the hamster cheek pouch in response to adenosine 5′-diphosphate and bradykinin. Inflammation. 16:1992;295-305.
20. Mayhan W. G. Cerebral circulation during diabetes mellitus. Pharmacol. Ther. 57:1993a;377-391.
21. 4-induced increases in microvascular transport. Am. J. Physiol. 265:1993b;H409-H414.
22. Mayhan W. G. Nitric oxide accounts for histamine-induced increases in macromolecular extravasation. Am. J. Physiol. 266:1994;H2369-H2373.
23. Mayhan W. G. l-Arginine does not reverse impaired agonist-induced increases in macromolecular efflux during diabetes mellitus. Cardiovasc. Res. 34:1997;215-222.
24. Mayhan W. G., Patel K. P., Sharpe G. M. Effect of l-arginine on reactivity of hamster cheek pouch arterioles during diabetes mellitus. Int. J. Microcirc. 17:1997;107-112.
25. Mayhan W. G., Sharpe G. M. Superoxide dismutase restores impaired histamine-induced increases in venular macromolecular efflux during diabetes mellitus. Microcirculation. 5:1998;211-218.
26. Mayhan W. G. VEGF increases permeability of the blood-brain barrier via a nitric oxide synthase/cGMP-dependent pathway. Am. J. Physiol. 276:1999;C1148-C1153.
27. McDaniel M. L., Kwon G., Hill J. R., Marshall C. A., Corbett J. A. Cytokines and nitric oxide in islet inflammation and diabetes. Proc. Soc. Exp. Biol. Med. 211:1996;24-32.
28. Minc-Golomb D., Tsarfaty I., Schwartz J. P. Expression of inducible nitric oxide synthase by neurones following exposure to endotoxin and cytokine. Br. J. Pharmacol. 112:1994;720-722.
29. Misko T. P., Moore W. M., Kasten T. P., Nickols G. A., Corbett J. A., Tilton R. G., McDaniel M. L., Williamson J. R., Currie M. G. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur. J. Pharmacol. 233:1993;119-125.
30. Miyamoto K., Hiroshiba N., Tsujikawa A., Ogura Y. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Ophthalmol. Vis. Sci. 39:1998;2190-2194.
31. Nakamura T., Fukui M., Ebihara I., Osada S., Nagaoka I., Tomino Y., Koide H. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes. 42:1993;450-456.
32. Nathan D. M. Long-term complications of diabetes mellitus. N. Engl. J. Med. 328:1993;1676-1685.
33. Oliver J. A. Endothelium-derived relaxing factor contributes to the regulation of endothelial permeability. J. Cell Physiol. 151:1992;506-511.
34. Parving H. Increased microvascular permeability to plasma proteins in short- and long-term juvenile diabetes. Diabetes. 25:1976;884-889.
35. Phares C. K. Streptozotocin-induced diabetes in Syrian hamsters: New model of diabetes mellitus. Experientia. 36:1980;681-682.
36. Pieper G. M., Gross G. J. Endothelial dysfunction in diabetes. Rubanyi G. M. Cardiovascular Significance of Endothelium-Derived Vasoactive Factors. 1991;223-249 Futura Publishing Co. Mount Kisco.
37. Sirois M. G., Edelman E. R. VEGF effect on vascular permeability is mediated by synthesis of platelet activating factor. Am. J. Physiol. 272:1997;H2746-H2756.
38. Stehouwer C. D. A., Lambert J., Donker A. J. M., Van Hinsbergh V. W. M. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc. Res. 34:1997;55-68.
39. Tilton R. G., Chang K., Hasan K. S., Smith S. R., Petrash J. M., Misko T. P., Moore W. M., Currie M. G., Corbett J. A., McDaniel M. L., Williamson J. R. Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes. 42:1993;221-232.
40. Tomlinson K. C., Gardiner S. M., Hebden R. A., Bennett T. Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. Pharmacol. Rev. 44:1992;103-150.
41. Tooke J. E. Microcirculation and diabetes. Br. Med. Bull. 45:1989;206-223.
42. G-monomethyl-l-arginine on the onset of diabetes in the spontaneously diabetic BB rat. Diabetes. 44:1995;360-364.
43. Wu H. M., Huang Z., Yuan Y., Granger H. J. VEGF induces NO-dependent hyperpermeability in coronary venules. Am. J. Physiol. 271:1996;H2735-H2739.
44. Yamamoto T., Nakamura T., Noble N. A., Ruoslahti E., Border W. A. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc. Natl. Acad. Sci. USA. 90:1993;1814-1818.
45. Yuan Y., Granger H. J., Zawieja D. C., Chilian W. M. Flow modulates coronary venular permeability by a nitric oxide-related mechanism. Am. J. Physiol. Heart Circ. Physiol. 263:1992;H641-H646.